The Max Foundation, an international health organization dedicated to serving cancer patients, and Tanner Pharma Group are committed partners in bringing thousands of patients around the globe daily access to cancer treatment.

Tanner Pharma Group has announced the signing of a distribution agreement with Partner Therapeutics, Inc. (PTx). The agreement names Tanner Pharma Group as a distributor of Leukine® (sargramostim) in areas outside of the United States and Canada where the product is not yet registered.

The Max Foundation and Tanner Pharma Group have partnered to create an innovative distribution model designed to effectively deliver humanitarian donations of oncology products to identified patients in need in low resource countries.

Tanner Pharma Group’s Managed Access Programs (MAP) division and Proveca have agreed to launch a Managed Access Program for an oral formulation of glycopyrronium (Sialanar®) outside Europe and the USA.

Tanner Pharma Group is proud to serve as the title sponsor for The Max Foundation’s "Max Global Experience: Uganda," an expedition to raise awareness and funds for increased cancer treatment access in Africa.

Tanner Pharmaceuticals, Inc. and BurnsAdler Pharmaceuticals have merged to form Tanner Pharma Group.

The agreement names Tanner Pharma Group as Merz North America’s sole Named Patient distributor of Cuvposa ® (glycopyrrolate) oral solution in Latin America where Cuvposa ® (glycopyrrolate) oral solution is not yet registered.